PDCD1 and neoplasm: On the other hand, analysis of pre- and post-immunotherapy tumor samples obtained upon recurrence, months after treatment with PD-1 blockade, showed that responder patients to this immunotherapy had decreased MARCO expression in recurrent GBM samples [28], a phenomenon not seen in a longitudinal analysis of GBMs treated with chemoradiotherapy [98].